Drug intelligence / Profile preview

CRIS100

Development stage: Phase 1
Lead developer: Cristália
Modality: Antibody-Based Therapeutics

Overview

CRIS100 is an investigational antibody therapy developed for the treatment of acute spinal cord injury, specifically targeting injuries to the thoracic spinal cord. The drug is being evaluated in early phase clinical trials to assess its safety and efficacy when administered directly into the epicenter of a spinal injury within 72 hours of trauma. The precise mechanism of action and molecular target for this antibody remain undisclosed as of the latest available data. The developer and sponsor for clinical studies is Cristália Produtos Químicos Farmacêuticos Ltda.[1][2][4][5]

Other names: CRIS100CRIS-100CRIS 100

Beyond the preview

Go deeper on CRIS100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRIS100.

Explore the full profile